Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

RLYB

Rallybio Corp

May 15 • 04:00PM ET

1.91

Dollar change +0.07
Percentage change 3.80	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI IWN VXF VTWO IWC VTWV AVSC URTY VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.88	Insider Own	46.38%	Shs Outstand	37.83M	Perf Week	3.24%
Market Cap	79.17M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	0.00%	Shs Float	22.22M	Perf Month	6.11%
Income	-76.28M	PEG	-	EPS next Q	-0.37	Inst Own	32.77%	Short Float	8.81%	Perf Quarter	11.70%
Sales	0.00M	P/S	-	EPS this Y	17.97%	Inst Trans	0.44%	Short Ratio	1.22	Perf Half Y	-24.80%
Book/sh	2.36	P/B	0.81	EPS next Y	7.83%	ROA	-58.30%	Short Interest	1.96M	Perf Year	-64.89%
Cash/sh	2.27	P/C	0.84	EPS next 5Y	-	ROE	-62.43%	52W Range	1.23 - 9.14	Perf YTD	-20.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-35.52%	ROI	-85.44%	52W High	-79.10%	Beta	-1.61
Dividend TTM	-	Quick Ratio	9.77	Sales past 5Y	0.00%	Gross Margin	-	52W Low	55.92%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	9.77	EPS Y/Y TTM	8.67%	Oper. Margin	0.00%	RSI (14)	53.60	Volatility	7.51% 8.32%
Employees	43	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	13.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-8.46%	Payout	-	Rel Volume	0.14	Prev Close	1.84
Sales Surprise	-	EPS Surprise	0.72%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	1.60M	Price	1.91
SMA20	6.23%	SMA50	7.81%	SMA200	-35.07%	Trades		Volume	227,341	Change	3.80%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-07-24	Downgrade	Jefferies	Buy → Hold	$7 → $1.50
Apr-17-23	Initiated	H.C. Wainwright	Buy	$18
Apr-10-23	Initiated	Wedbush	Outperform	$17
Dec-09-22	Initiated	JP Morgan	Overweight	$21
Feb-22-22	Initiated	JMP Securities	Mkt Outperform	$32
Aug-23-21	Initiated	Jefferies	Buy	$20
Aug-23-21	Initiated	Evercore ISI	Outperform	$40
Aug-23-21	Initiated	Cowen	Outperform

May-10-24 06:30AM	3 Biotech Stocks to Sell in May Before They Crash & Burn (InvestorPlace)
May-09-24 01:54PM	RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024 (InvestorPlace)
10:14AM	Rallybio reins in preclinical R&D, while Monopar pivots to radiopharma to eke out cash (FierceBiotech.com)
08:00AM	Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
May-07-24 08:00AM	Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference (Business Wire)
04:01PM	Loading…
Apr-17-24 04:01PM	FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting (Business Wire)
Apr-12-24 10:23AM	RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up (Zacks) -26.17%
Apr-11-24 07:43AM	Why Is Rallybio (RLYB) Stock Up 93% Today? (InvestorPlace) +82.82%
Apr-10-24 04:01PM	Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (Business Wire)
01:01PM	J&J, Rallybio partner on drug development for rare fetal condition (BioPharma Dive)
Apr-01-24 10:05AM	Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting (Business Wire)
Mar-12-24 08:00AM	Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -8.70%
Feb-26-24 08:00AM	Rallybio to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire) +5.88%
Feb-06-24 09:46AM	Rallybio, with financial fuel levels falling, loses 45% of workforce to extend cash runway into 2026 (FierceBiotech.com) +24.00%
08:00AM	Rallybio Announces Portfolio Prioritization and Provides Corporate Update (Business Wire)
08:00AM	Loading…
Jan-04-24 08:00AM	Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024 (Business Wire)
Dec-20-23 08:00AM	Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 (Business Wire) -5.50%
Dec-09-23 12:00PM	Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting (Business Wire)
Nov-28-23 07:00AM	Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire) -10.00%
Nov-09-23 08:00AM	Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Nov-08-23 08:00AM	Rallybio to Present at Upcoming Investor Conferences in November (Business Wire) -12.79%
Nov-02-23 09:15AM	Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting (Business Wire)
Oct-03-23 08:00AM	Rallybio to Present at the JonesTrading 2023 Healthcare Summit (Business Wire) +10.14%
Sep-03-23 12:00PM	Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 (Business Wire)
Aug-31-23 08:00AM	Rallybio to Present at Upcoming Investor Conferences in September (Business Wire)
Aug-08-23 08:00AM	Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Aug-02-23 08:00AM	Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference (Business Wire)
Jul-11-23 08:00AM	Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) (Business Wire)
Jun-29-23 07:00AM	Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023 (Business Wire) -5.57%
Jun-24-23 03:30PM	Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire)
09:15AM	Loading…
Jun-09-23 09:15AM	Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis (Business Wire)
Jun-01-23 08:00AM	Rallybio to Present at the Jefferies Healthcare Conference (Business Wire) +6.01%
May-29-23 09:55AM	Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade (Zacks)
May-12-23 09:55AM	Does Rallybio Corporation (RLYB) Have the Potential to Rally 290.63% as Wall Street Analysts Expect? (Zacks)
May-09-23 08:00AM	Rallybio Reports First Quarter 2023 Financial Results (Business Wire) -7.00%
May-08-23 08:00AM	Rallybio to Present at the JMP Securities 2023 Life Sciences Conference (Business Wire) +6.57%
Apr-06-23 08:00AM	Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis (Business Wire)
Apr-03-23 08:00AM	Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) (Business Wire)
Mar-15-23 09:15AM	We're Not Very Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Rate (Simply Wall St.)
Mar-10-23 09:35AM	Down -19.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Rallybio Corporation (RLYB) (Zacks)
Mar-06-23 02:49PM	Rallybio Pulls Plug On One Candidate After Highlighting Encouraging Data From Another Thrombocytopenia Program (Benzinga) +10.34%
08:00AM	Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
07:30AM	Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire)
Mar-02-23 09:01AM	EyePoint Pharma Takes $20.7M Intangible Impairment Charge In Q4, Shares Pipeline Update, Expects Cash Runway Into 2024 (Benzinga)
Mar-01-23 08:00AM	Rallybio to Present at Upcoming Investor Conferences in March (Business Wire)
Feb-27-23 07:00AM	EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybios Inhibitor of Complement Component 5 (C5) and EyePoints Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy (Business Wire)
Jan-31-23 04:05PM	Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer (Business Wire)
Jan-05-23 08:00AM	Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023 (Business Wire)
Dec-15-22 08:00AM	Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT (Business Wire) +11.25%
Dec-14-22 06:39AM	Rallybio Corporation (NASDAQ:RLYB) insiders are still down US$129k after purchasing last year, recent gain helped regain some losses (Simply Wall St.) +6.95%
Dec-12-22 05:55PM	2 Strong Buy Stocks J.P. Morgan Predicts Will Surge Over 50% (TipRanks) -5.27%
Dec-01-22 07:00AM	AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases (Business Wire)
Nov-29-22 08:00AM	Rallybio to Present at the JMP Securities Hematology and Oncology Summit (Business Wire) -7.53%
Nov-17-22 05:39AM	Private equity firms who have a significant stake must be disappointed along with institutions after Rallybio Corporation's (NASDAQ:RLYB) market cap dropped by US$54m (Simply Wall St.) +7.65%
Nov-11-22 08:00AM	Rallybio to Present at Upcoming Investor Conferences in November (Business Wire) -16.57%
Nov-10-22 11:51PM	Rallybio Announces Pricing of $50 Million Public Offering (Business Wire) -16.56%
09:15AM	Rallybio Announces Proposed Public Offering (Business Wire)
Nov-07-22 08:00AM	Rallybio Reports Third Quarter 2022 Financial Results (Business Wire)
07:30AM	Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 (Business Wire)
Oct-06-22 08:38AM	Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) +5.26%
Sep-28-22 12:37PM	Rallybio's Thrombocytopenia Candidate Shows Rapid, Complete Elimination Of Transfused Platelets (Benzinga)
08:00AM	Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire)
Aug-31-22 08:00AM	Rallybio to Present at the 2022 Wells Fargo Healthcare Conference (Business Wire)
Aug-08-22 08:00AM	Rallybio Reports Second Quarter 2022 Financial Results (Business Wire) -5.78%
Aug-02-22 08:00AM	Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors (Business Wire)
Jul-06-22 07:37AM	Multiple insiders bought Rallybio Corporation (NASDAQ:RLYB) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Jun-02-22 08:30AM	Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer (Business Wire)
Jun-01-22 08:00AM	Rallybio to Present at Upcoming Investor Conferences in June (Business Wire)
May-10-22 08:00AM	Rallybio Reports First Quarter 2022 Financial Results (Business Wire) +6.05%
07:30AM	Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi (Business Wire)
Apr-29-22 08:36AM	We're Hopeful That Rallybio (NASDAQ:RLYB) Will Use Its Cash Wisely (Simply Wall St.)
Apr-28-22 11:45AM	10 Best Stocks Under $20 According to Billionaire Andreas Halvorsens Viking Global (Insider Monkey)
Apr-04-22 08:00AM	Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors (Business Wire) +7.03%
Mar-15-22 08:00AM	Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) -10.56%
Feb-28-22 08:00AM	Rallybio to Present at the Cowen 42nd Annual Health Care Conference (Business Wire) -5.09%
Jan-27-22 08:49AM	Great news for Rallybio Corporation (NASDAQ:RLYB): Insiders acquired stock in large numbers last year (Simply Wall St.) +6.80%
Jan-18-22 08:00AM	Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate Communications (Business Wire) -6.09%
Jan-06-22 08:00AM	Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022 (Business Wire) +6.76%
Dec-30-21 05:33AM	Rallybio (RLYB) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Dec-08-21 07:38PM	Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ... (GuruFocus.com)
07:38PM	Tekla Healthcare Opportunities Fund Buys Moderna Inc, IDEXX Laboratories Inc, Sarepta ... (GuruFocus.com)
07:38PM	Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ... (GuruFocus.com)
Dec-01-21 07:26AM	Rallybio (RLYB) Sees Hammer Chart Pattern: Time to Buy? (Zacks) -8.00%
07:00AM	Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (Business Wire)
Nov-24-21 08:00AM	Rallybio Corporation to Present at the 4th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-11-21 08:00AM	Rallybio to Present at the Jefferies London Healthcare Conference (Business Wire) -12.10%
Nov-10-21 07:00AM	Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights (Business Wire) +5.07%
Oct-29-21 10:49AM	We're Not Very Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Rate (Simply Wall St.) +6.12%
Sep-09-21 07:00AM	Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights (Business Wire)
Aug-02-21 04:05PM	Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (Business Wire) +5.88%
Jul-28-21 09:10PM	Rallybio Corporation Announces Pricing of Initial Public Offering (Business Wire)

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RLYB

Rallybio Corp

Upgrade your FINVIZ experience